The FreMRI Study: Advanced MRI on Migraine Patients Treated With Fremanezumab

PHASE4RecruitingINTERVENTIONAL
Enrollment

87

Participants

Timeline

Start Date

March 1, 2023

Primary Completion Date

October 1, 2024

Study Completion Date

January 1, 2025

Conditions
Migraine DisordersMigraine With AuraMigraine Without AuraBrain Diseases
Interventions
DRUG

Fremanezumab Prefilled Syringe

MRI will be scanned prior to the first administration of Fremanezumab, within 0-14 days, prior to Fremanezumab injection. The second MRI will be acquired at 12 ± 1 weeks after the first Fremanezumab injection.Images will be acquired during interictal periods, defined as at least 24 hours from last migraine attack. All the scans will be acquired during the same session, starting with the T1-weighted scan, followed by the diffusion-weighted scan and ending with the rs-fMRI scan. Total acquisition time for a single subject is approximately 28 minutes, divided in the following periods of time: six minutes for the T1-weighted scan, 12 minutes for the diffusion-weighted scan and 10 minutes for the rs-fMRI scan. If we consider patient preparation, obtainment of documents and informed consent form, the whole process will take about 50-70 minutes.

Trial Locations (1)

47010

RECRUITING

Hospital Clínico Universitario de Valladolid, Valladolid

All Listed Sponsors
collaborator

University of Valladolid

OTHER

collaborator

Complejo Asistencial Universitario de Palencia

UNKNOWN

collaborator

Complejo Público Asistencial de Zamora

UNKNOWN

lead

Hospital Clínico Universitario de Valladolid

OTHER